A combination of pembrolizumab and an antibody-drug conjugate demonstrated a 73% overall response rate in a phase 1/2 clinical trial.
Age, BMI, and education may indicate physical activity levels in men seeking genetic counseling and/or testing for prostate cancer.
Assessments and interventions for younger and female patients with RCC may need to be targeted, as these patients may have a greater fear of disease recurrence.
The VES-13, a brief frailty screening tool, was found effective in determining which older patients with GU cancer were at higher risk for adverse outcomes and would benefit from a CGA.
Findings of a prospective study demonstrated that the psychological impact of a cancer diagnosis can be significant even with cancers that have a good prognosis.
Patients with GU malignancies were more likely to receive palliative care if they were in the West compared with other US regions.
In a long-term follow-up of the CheckMate trial, investigators observed consistently prolonged survival with nivolumab compared with everolimus.
In a single-center study of 177 patients with metastatic renal cell carcinoma who received at least a single dose of an immune checkpoint inhibitor, the median time to next treatment was 8.9 months and median overall survival time was 26.7 months.
In a study, metastasectomy was associated with significantly longer median progression-free and overall survival in some mRCC patients.
Bone metastases less predictive in the setting of cytoreductive nephrectomy.